 Connection
Erin Harvey to Anti-Asthmatic Agents
This is a "connection" page, showing publications Erin Harvey has written about Anti-Asthmatic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.495 |
|
|
|
-
Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, Bardin P, Peters M, Reynolds PN, Upham JW, Baraket M, Bowler S, Bowden J, Chien J, Chung LP, Grainge C, Jenkins C, Katsoulotos GP, Lee J, McDonald VM, Reddel HK, Rimmer J, Wark PAB, Gibson PG. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020 05; 55(5).
Score: 0.513
-
Thomas D, Lewthwaite H, Gibson PG, Majellano E, Clark V, Fricker M, Hamada Y, Anderson GP, Backer V, Bardin P, Beasley R, Chien J, Farah CS, Harrington J, Harvey E, Hew M, Holland AE, Jenkins C, Katelaris CH, Katsoulotos G, Murray K, Peters M, Thomas R, Tonga K, Upham JW, Wark P, McDonald VM. Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion. Respirology. 2025 Jun; 30(6):466-479.
Score: 0.181
-
Hamada Y, Thomas D, Harvey ES, Stevens S, Fricker M, Lewthwaite H, McDonald VM, Gillman A, Hew M, Kritikos V, Upham JW, Gibson PG. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. Eur Respir J. 2025 Jan; 65(1).
Score: 0.178
-
Hamada Y, Gibson PG, Harvey ES, Stevens S, Lewthwaite H, Fricker M, McDonald VM, Gillman A, Hew M, Kritikos V, Upham JW, Thomas D. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2025 Feb; 13(2):333-342.e9.
Score: 0.175
-
Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, Bowden JJ, Bowler S, Chien J, Chung LP, Gillman A, Hew M, Hodge S, James A, Jenkins C, Katelaris CH, Katsoulotos GP, Langton D, Lee J, Marks G, Peters M, Radhakrishna N, Reynolds PN, Rimmer J, Sivakumaran P, Upham JW, Wark P, Yang IA, Gibson PG. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024 02; 79(2):384-392.
Score: 0.161
-
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG. Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2023 03; 11(3):885-895.e13.
Score: 0.153
-
Thomas D, Harvey ES, McDonald VM, Stevens S, Upham JW, Katelaris CH, Kritikos V, Gillman A, Harrington J, Hew M, Bardin P, Peters M, Reynolds PN, Langton D, Baraket M, Bowden JJ, Bowler S, Chien J, Chung LP, Farah CS, Grainge C, Jenkins C, Katsoulotos GP, Lee J, Radhakrishna N, Reddel HK, Rimmer J, Sivakumaran P, Wark PAB, Gibson PG. Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. J Allergy Clin Immunol Pract. 2021 07; 9(7):2715-2724.e5.
Score: 0.135
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|